ID   TMK-1
AC   CVCL_4384
SY   TMK1
DR   BTO; BTO:0003219
DR   EFO; EFO_0002867
DR   CCLE; TMK1_STOMACH
DR   Cell_Model_Passport; SIDM00040
DR   Cosmic; 887251
DR   Cosmic; 888829
DR   Cosmic; 897537
DR   Cosmic; 922689
DR   Cosmic; 926110
DR   Cosmic; 1122341
DR   Cosmic; 1187298
DR   Cosmic; 1223585
DR   Cosmic; 1460701
DR   Cosmic; 1482078
DR   Cosmic; 1518245
DR   Cosmic; 1571762
DR   Cosmic-CLP; 1299069
DR   DepMap; ACH-002202
DR   GDSC; 1299069
DR   GEO; GSM552377
DR   GEO; GSM562397
DR   IARC_TP53; 974
DR   PharmacoDB; TMK1_1601_2019
DR   TOKU-E; 4022
DR   Wikidata; Q54972697
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=1370612;
RX   PubMed=1933850;
RX   PubMed=11107048;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: TP53 p.Val173Met (c.517G>A) (PubMed=1370612; PubMed=1933850).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.05%; Native American=0.49%; East Asian, North=70.76%; East Asian, South=27.97%; South Asian=0%; European, North=0.73%; European, South=0% (PubMed=30894373).
CC   Derived from metastatic site: Lymph node.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,13
ST   D16S539: 9
ST   D5S818: 10,13
ST   D7S820: 8,12
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_F953 ! SC-6-JCK
SX   Male
AG   21Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 19
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//